Gastroesophageal Cancer

Tezacitabine program to be discontinued based on phase II trial analysis

Published in Cancer Weekly, April 13th, 2004

Chiron Corporation (CHIR) announced that the company has decided to discontinue further development of tezacitabine, a next-generation nucleoside analog, based on an analysis of the data from a phase II trial in patients with gastroesophageal cancer.

The compound did not demonstrate sufficient antitumor activity in the trial to satisfy Chiron's predetermined criteria to advance the program. The company had previously announced that it had concluded phase II development of tezacitabine in patients with colorectal cancer. No safety issues were identified in treatment with tezacitabine.

"Data from the phase II trial failed to meet Chiron's threshold for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-04-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry